查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1496205

癌症免疫治療市場：2024-2034

Cancer Immunotherapy Market Report 2024-2034
出版日期: | 出版商: Visiongain | 英文 286 Pages | 商品交期: 最快1-2個工作天內

價格

預計到 2034 年，全球癌症免疫治療市場規模將以 12.6% 的複合年增長率成長。

癌症發生率的增加和癌症免疫療法研究推動市場成長：

根據世界衛生組織 (WHO) 2024 年 2 月發佈的數據，癌症是全球主要死亡原因，2022 年將新增約 2,000 萬癌症病例，死亡人數超過 900 萬人。美國癌症協會預測，由於人口老化和人口成長，到2040年，全球癌症患者數量將超過2,800萬人。北美的癌症死亡人數和新病例數均排名第四，而中國作為世界人口最多的國家，兩者的發生率均位居全球最高。由於全球飲酒和吸煙增加、不良飲食習慣、缺乏運動以及空氣污染加劇等因素，未來癌症負擔可能會增加。

近年來，免疫療法等最新的癌症治療方法已經徹底改變了這個領域。癌症免疫療法是讓研究人員和腫瘤學家非常興奮的一種治療方法。經過多年的深入研究，癌症免疫療法現已在全世界範圍內用於治療癌症。例如，生物醫學這項研究的目的是利用嗜中性球的抗癌作用來開發下一代免疫療法。因此，推動該市場成長的主要因素是對改進免疫治療方法的持續研究以及用於癌症治療的新型免疫療法的持續開發。

本報告調查了全球癌症免疫治療市場，並提供了市場概況、影響市場成長和市場機會的因素分析、市場規模趨勢和預測，以及依各個細分市場、地區和主要國家進行的細分。

目錄

第 1 章報告概述

第 2 章執行摘要

第三章市場概述

  • 主要發現
  • 市場動態
  • 影響分析
    • 市場驅動因素
    • 市場限制因素
    • 市場機會
  • 供應鏈分析
  • 監理框架
  • 新興市場與大趨勢
  • 波特五力分析
  • PEST分析

第 4 章癌症免疫治療市場分析：依技術

  • 主要調查結果
  • 市場吸引力指數
  • 市場規模趨勢與預測
  • 單株抗體
  • 免疫調節藥物
  • 其他
    • 市場規模趨勢與預測：依地區劃分
    • 市佔率：依地區劃分

第五章癌症免疫治療市場分析：依應用

  • 主要調查結果
  • 市場吸引力指數
  • 市場規模趨勢與預測
  • 肺癌
  • 乳癌
  • 大腸癌
  • 惡性黑色素瘤
  • 攝護腺癌
  • 頭頸癌
  • 卵巢癌
  • 胰臟癌
  • 其他
    • 市場規模趨勢與預測：依地區劃分
    • 市佔率：依地區劃分

第 6 章癌症免疫治療市場分析：依最終使用者

  • 主要調查結果
  • 市場吸引力指數
  • 市場規模趨勢與預測
  • 醫院
  • 癌症研究中心
  • 診所
    • 市場規模趨勢與預測：依地區劃分
    • 市佔率：依地區劃分

第七章癌症免疫治療市場分析：依地區

  • 主要調查結果
  • 市場規模趨勢與預測

第八章北美癌症免疫治療市場分析

第九章歐洲癌症免疫治療市場分析

第十章亞太地區癌症免疫治療市場分析

第11章拉丁美洲癌症免疫治療市場分析

第十二章中東與非洲癌症免疫治療市場分析

第十三章公司簡介

  • 競爭狀況
  • 戰略展望
  • F. Hoffmann-La Roche Ltd.
  • Merck &Co., Inc.
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Bayer AG
  • AstraZeneca
  • Lilly
  • Pfizer Inc.
  • Johnson &Johnson Services, Inc.
  • GSK plc
  • Gilead Sciences, Inc.
  • Amgen Inc.
  • AbbVie Inc.
  • Immunocore Ltd.
  • Sanofi
  • Takeda Pharmaceutical Company Limited.

第 14 章一般性評論/建議

  • Visiongain 概述
  • 對進入市場的公司的建議
Product Code: PHA1340

The global Cancer Immunotherapy market is projected to grow at a CAGR of 12.6% by 2034

The Cancer Immunotherapy Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Increasing Prevalence of Cancer and Increasing Research in Cancer Immunotherapy are driving the Market Growth

Cancer is a major cause of death worldwide, accounting for about 20 million new cancer cases and over 9 million deaths in 2022, according to data released by the World Health Organisation in February 2024. By 2040, the American Cancer Society, Inc. projects that the global cancer burden would have increased to over 28 million cases due to present and anticipated population ageing and growth. North America is fourth in terms of cancer deaths and fourth in terms of new cases, whereas China, which has the greatest population in the world, has the highest global proportion of both. The cancer burden may rise in the future due to factors such increased alcohol and tobacco use, poor diet, physical inactivity, and air pollution in many different parts of the world.

Modern cancer treatments, such as those based on immunotherapy, have revolutionised the field in recent years. One such treatment that has greatly excited researchers and oncologists is cancer immunotherapy. Globally, cancer immunotherapy is being used as a treatment for cancer after years of intensive research. For instance, the German biomedical research institute BioMed X and one of the biggest pharmaceutical corporations in Japan, Ono Pharmaceutical Co., Ltd., announced in December 2023 the commencement of a new cooperative research initiative. Using neutrophils' anticancer properties to create next-generation immunotherapies is the aim of this research endeavour. Therefore, the primary driver propelling the growth of this market is the ongoing research into how to improve immunotherapy and the ongoing development of novel immunotherapies for the treatment of cancer.

Reimbursement Challenges, High Cost and Side-effects may Hamper Cancer Immunotherapy Growth

Healthcare providers, insurance companies, and national and local government organisations all around the world have faced difficulties in getting reimbursement for cancer immunotherapy treatments. Cancer immunotherapy is one of the priciest medications available, costing more than $100,000 per patient. This covers the price of medications, hospital stays, and multiple days of intensive care because many patients receiving cancer immunotherapy treatments have serious adverse effects.

The Keytruda maker, Merck, states that the out-of-pocket expenses for each infusion might vary from $1,000 to $1,950. However, this rate can still be excessively expensive for many patients. In the event that the patient has Medigap or Medicare Advantage (Part C), additional coverage may be obtained. The Keytruda treatment may potentially be completely covered, depending on the plan. In actuality, 41% of patients with Medicare Advantage Plans reported having no out-of-pocket costs, according to Merck. Patients in developing nations cannot afford the high cost of immunotherapy medications. One of the main obstacles facing businesses developing immunotherapy medications is high pricing. Thus, it is one of the main factors impeding this market's growth over the predicted period.

What Questions Should You Ask Before Buying a Market Research Report?

How is the cancer immunotherapy market evolving?

What is driving and restraining the cancer immunotherapy market?

How will each point of care diagnostic submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?

How will the market shares for each cancer immunotherapy submarket develop from 2024 to 2034?

What will be the main driver for the overall market from 2024 to 2034?

Will leading cancer immunotherapy markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?

How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?

Who are the leading players and what are their prospects over the forecast period?

What are the cancer immunotherapy projects for these leading companies?

How will the industry evolve during the period between 2024 and 2034? What are the implications of cancer immunotherapy projects taking place now and over the next 10 years?

Is there a greater need for product commercialisation to further scale the cancer immunotherapy market?

Where is the cancer immunotherapy market heading and how can you ensure you are at the forefront of the market?

What are the best investment options for new product and service lines?

What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Cancer Immunotherapy market today, and over the next 10 years:

Our 286-page report provides 117 tables, 189 charts/graphs exclusively to you.

The report highlights key lucrative areas in the industry so you can target them - NOW.

It contains in-depth analysis of global, regional and national sales and growth.

It highlights for you the key successful trends, changes and revenue projections made by your competitors.

Forecasts to 2034 and other analyses reveal commercial prospects

In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.

You will find original analyses, with business outlooks and developments.

Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), impact of rising Cancer Immunotherapy prices and recent developments.

Segments Covered in the Report

Technology

Monoclonal Antibodies

Immunomodulators

Other Technology

Application

Lung Cancer

Breast Cancer

Colorectal Cancer

Melanoma

Prostate Cancer

Head & Neck Cancer

Ovarian Cancer

Pancreatic Cancer

Others

End-users

Hospitals

Cancer Research Centres

Clinics

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 25 leading national markets:

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Switzerland

Netherlands

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

South East Asia

Rest of Asia Pacific

Latin America

Brazil

Mexico

Argentina

Rest of Latin America

MEA

GCC

South Africa

Egypt

Rest of MEA

The report also includes profiles for some of the leading companies in the Cancer Immunotherapy Market, 2024 to 2034, with a focus on this segment of these companies' operations.

Leading companies profiled in the report

AbbVie Inc.

Amgen Inc.

AstraZeneca

Bayer AG

Bristol-Myers Squibb Company

F. Hoffmann-La Roche Ltd.

Gilead Sciences, Inc.

GSK plc

Immunocore Ltd.

Johnson & Johnson Services, Inc.

Lilly

Merck & Co., Inc.

Novartis AG

Pfizer Inc.

Sanofi

Takeda Pharmaceutical Company Limited

Overall world revenue for Cancer Immunotherapy Market, 2024 to 2034 in terms of value the market will surpass US$135.0 billion in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Cancer Immunotherapy Market, 2024 to 2034 report help you?

In summary, our 280+ page report provides you with the following knowledge:

Revenue forecasts to 2034 for Cancer Immunotherapy Market, 2024 to 2034, with forecasts for technology, application, end-users, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.

Revenue forecasts to 2034 for five regional and 25 key national markets - See forecasts for the Cancer Immunotherapy Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, Spain, Switzerland, Netherlands, China, India, Japan, Australia, South Korea, South East Asia, Argentina, GCC, South Africa, and Egypt among other prominent economies.

Prospects for established firms and those seeking to enter the market - including company profiles for 16 of the major companies involved in the Cancer Immunotherapy Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Cancer Immunotherapy Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Cancer Immunotherapy Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report for?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
  • 3.3 Impact Analysis
    • 3.3.1 Market Driving Factors
      • 3.3.1.1 Increasing Prevalence of Cancer
      • 3.3.1.2 Increasing Research in Cancer Immunotherapy
      • 3.3.1.3 Increasing Funding for the Cancer Research by Government, Public and Private Sector
    • 3.3.2 Market Restraining Factors
      • 3.3.2.1 Reimbursement Challenges for Cancer immunotherapy
      • 3.3.2.2 High Cost and Side-effects of Cancer Immunotherapy
    • 3.3.3 Market Opportunities
      • 3.3.3.1 Increased Focus towards Advanced Treatment Protocols
      • 3.3.3.2 Significant Unmet Need in Cancer Diagnosis
      • 3.3.3.3 Growing use of AI in Cancer immunotherapy Manufacturing
  • 3.4 Supply Chain Analysis
  • 3.5 Regulatory Framework
  • 3.6 Emerging Markets and Megatrends
  • 3.7 Porter's Five Forces Analysis
    • 3.7.1 Bargaining Power of Buyers (High)
    • 3.7.2 Bargaining Power of Suppliers (Low)
    • 3.7.3 Threat of New Entrants (Low)
    • 3.7.4 Threat of Substitute Products (High)
    • 3.7.5 Intensity of Competitive Rivalry (High)
  • 3.8 PEST Analysis

4 Cancer Immunotherapy Market Analysis by Technology

  • 4.1 Key Findings
  • 4.2 Technology Segment: Market Attractiveness Index
  • 4.3 Cancer Immunotherapy Market Size Estimation and Forecast by Technology
  • 4.4 Monoclonal Antibodies
    • 4.4.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.4.2 Market Share by Region, 2024 & 2034 (%)
  • 4.5 Immunomodulators
    • 4.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.5.2 Market Share by Region, 2024 & 2034 (%)
  • 4.6 Other Technology
    • 4.6.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.6.2 Market Share by Region, 2024 & 2034 (%)

5 Cancer Immunotherapy Market by Application

  • 5.1 Key Findings
  • 5.2 Application Segment: Market Attractiveness Index
  • 5.3 Cancer Immunotherapy Market, by Application
  • 5.4 Lung Cancer
    • 5.4.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.4.2 Market Share by Region, 2024 & 2034 (%)
  • 5.5 Breast Cancer
    • 5.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.5.2 Market Share by Region, 2024 & 2034 (%)
  • 5.6 Colorectal Cancer
    • 5.6.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.6.2 Market Share by Region, 2024 & 2034 (%)
  • 5.7 Melanoma
    • 5.7.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.7.2 Market Share by Region, 2024 & 2034 (%)
  • 5.8 Prostate Cancer
    • 5.8.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.8.2 Market Share by Region, 2024 & 2034 (%)
  • 5.9 Head & Neck Cancer
    • 5.9.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.9.2 Market Share by Region, 2024 & 2034 (%)
  • 5.10 Ovarian Cancer
    • 5.10.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.10.2 Market Share by Region, 2024 & 2034 (%)
  • 5.11 Pancreatic Cancer
    • 5.11.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.11.2 Market Share by Region, 2024 & 2034 (%)
  • 5.12 Others
    • 5.12.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.12.2 Market Share by Region, 2024 & 2034 (%)

6 Cancer Immunotherapy Market by End-users

  • 6.1 Key Findings
  • 6.2 End-users Segment: Market Attractiveness Index
  • 6.3 Cancer Immunotherapy Market by End-users Forecast, 2024-2034
  • 6.4 Hospitals
    • 6.4.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.4.2 Market Share by Region, 2024 & 2034 (%)
  • 6.5 Cancer Research Centers
    • 6.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.5.2 Market Share by Region, 2024 & 2034 (%)
  • 6.6 Clinics
    • 6.6.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.6.2 Market Share by Region, 2024 & 2034 (%)

7 Cancer Immunotherapy Market Analysis by Region

  • 7.1 Key Findings
  • 7.2 Regional Market Size Estimation and Forecast

8 North America Cancer Immunotherapy Market Analysis

  • 8.1 Key Findings
  • 8.2 North America Cancer Immunotherapy Market Attractiveness Index
  • 8.3 North America Cancer Immunotherapy Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 8.4 North America Cancer Immunotherapy Market Size Estimation and Forecast by Country
  • 8.5 North America Cancer Immunotherapy Market Size Estimation and Forecast by Technology
  • 8.6 North America Cancer Immunotherapy Market Size Estimation and Forecast by Application
  • 8.7 North America Cancer Immunotherapy Market Size Estimation and Forecast by End-users
  • 8.8 U.S. Cancer Immunotherapy Market Analysis
  • 8.9 Canada Cancer Immunotherapy Market Analysis

9 Europe Cancer Immunotherapy Market Analysis

  • 9.1 Key Findings
  • 9.2 Europe Cancer Immunotherapy Market Attractiveness Index
  • 9.3 Europe Cancer Immunotherapy Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 9.4 Europe Cancer Immunotherapy Market Size Estimation and Forecast by Country
  • 9.5 Europe Cancer Immunotherapy Market Size Estimation and Forecast by Technology
  • 9.6 Europe Cancer Immunotherapy Market Size Estimation and Forecast by Application
  • 9.7 Europe Cancer Immunotherapy Market Size Estimation and Forecast by End-users
  • 9.8 Germany Cancer Immunotherapy Market Analysis
  • 9.9 UK Cancer Immunotherapy Market Analysis
  • 9.10 France Cancer Immunotherapy Market Analysis
  • 9.11 Italy Cancer Immunotherapy Market Analysis
  • 9.12 Spain Cancer Immunotherapy Market Analysis
  • 9.13 Switzerland Cancer Immunotherapy Market Analysis
  • 9.14 Netherlands Cancer Immunotherapy Market Analysis
  • 9.15 Rest of Europe Cancer Immunotherapy Market Analysis

10 Asia Pacific Cancer Immunotherapy Market Analysis

  • 10.1 Key Findings
  • 10.2 Asia Pacific Cancer Immunotherapy Market Attractiveness Index
  • 10.3 Asia Pacific Cancer Immunotherapy Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 10.4 Asia Pacific Cancer Immunotherapy Market Size Estimation and Forecast by Country
  • 10.5 Asia Pacific Cancer Immunotherapy Market Size Estimation and Forecast by Technology
  • 10.6 Asia Pacific Cancer Immunotherapy Market Size Estimation and Forecast by Application
  • 10.7 Asia Pacific Cancer Immunotherapy Market Size Estimation and Forecast by End-users
  • 10.8 Japan Cancer Immunotherapy Market Analysis
  • 10.9 China Cancer Immunotherapy Market Analysis
  • 10.10 India Cancer Immunotherapy Market Analysis
  • 10.11 Australia Cancer Immunotherapy Market Analysis
  • 10.12 South Korea Cancer Immunotherapy Market Analysis
  • 10.13 South East Asia Cancer Immunotherapy Market Analysis
  • 10.14 Rest of Asia Pacific Cancer Immunotherapy Market Analysis

11 Latin America Cancer Immunotherapy Market Analysis

  • 11.1 Key Findings
  • 11.2 Latin America Cancer Immunotherapy Market Attractiveness Index
  • 11.3 Latin America Cancer Immunotherapy Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 11.4 Latin America Cancer Immunotherapy Market Size Estimation and Forecast by Country
  • 11.5 Latin America Cancer Immunotherapy Market Size Estimation and Forecast by Technology
  • 11.6 Latin America Cancer Immunotherapy Market Size Estimation and Forecast by Application
  • 11.7 Latin America Cancer Immunotherapy Market Size Estimation and Forecast by End-users
  • 11.8 Brazil Cancer Immunotherapy Market Analysis
  • 11.9 Mexico Cancer Immunotherapy Market Analysis
  • 11.10 Argentina Cancer Immunotherapy Market Analysis
  • 11.11 Rest of Latin America Cancer Immunotherapy Market Analysis

12 MEA Cancer Immunotherapy Market Analysis

  • 12.1 Key Findings
  • 12.2 MEA Cancer Immunotherapy Market Attractiveness Index
  • 12.3 MEA Cancer Immunotherapy Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 12.4 MEA Cancer Immunotherapy Market Size Estimation and Forecast by Country
  • 12.5 MEA Cancer Immunotherapy Market Size Estimation and Forecast by Technology
  • 12.6 MEA Cancer Immunotherapy Market Size Estimation and Forecast by Application
  • 12.7 MEA Cancer Immunotherapy Market Size Estimation and Forecast by End-users
  • 12.8 GCC Cancer Immunotherapy Market Analysis
  • 12.9 South Africa Cancer Immunotherapy Market Analysis
  • 12.10 Egypt Cancer Immunotherapy Market Analysis
  • 12.11 Rest of MEA Cancer Immunotherapy Market Analysis

13 Company Profiles

  • 13.1 Competitive Landscape, 2023
  • 13.2 Strategic Outlook
  • 13.3 F. Hoffmann-La Roche Ltd.
    • 13.3.1 Company Snapshot
    • 13.3.2 Company Overview
    • 13.3.3 Financial Analysis
      • 13.3.3.1 Net Revenue, 2019-2023
      • 13.3.3.2 R&D, 2019-2023
      • 13.3.3.3 Segment Market Shares, 2023
      • 13.3.3.4 Regional Market Shares, 2023
    • 13.3.4 Product Benchmarking
    • 13.3.5 Strategic Outlook
  • 13.4 Merck & Co., Inc.
    • 13.4.1 Company Snapshot
    • 13.4.2 Company Overview
    • 13.4.3 Financial Analysis
      • 13.4.3.1 Net Revenue, 2019-2023
      • 13.4.3.2 R&D, 2019-2023
      • 13.4.3.3 Segment Market Shares, 2023
      • 13.4.3.4 Regional Market Shares, 2023
    • 13.4.4 Product Benchmarking
    • 13.4.5 Strategic Outlook
  • 13.5 Novartis AG
    • 13.5.1 Company Snapshot
    • 13.5.2 Company Overview
    • 13.5.3 Financial Analysis
      • 13.5.3.1 Net Revenue, 2019-2023
      • 13.5.3.2 R&D, 2019-2023
      • 13.5.3.3 Segment Market Shares, 2023
      • 13.5.3.4 Regional Market Shares, 2023
    • 13.5.4 Product Benchmarking
    • 13.5.5 Strategic Outlook
  • 13.6 Bristol-Myers Squibb Company
    • 13.6.1 Company Snapshot
    • 13.6.2 Company Overview
    • 13.6.3 Financial Analysis
      • 13.6.3.1 Net Revenue, 2019-2023
      • 13.6.3.2 R&D, 2019-2023
      • 13.6.3.3 Segment Market Shares, 2023
      • 13.6.3.4 Regional Market Shares, 2023
    • 13.6.4 Product Benchmarking
    • 13.6.5 Strategic Outlook
  • 13.7 Bayer AG
    • 13.7.1 Company Snapshot
    • 13.7.2 Company Overview
    • 13.7.3 Financial Analysis
      • 13.7.3.1 Net Revenue, 2019-2023
      • 13.7.3.2 R&D, 2019-2023
      • 13.7.3.3 Segment Market Shares, 2023
      • 13.7.3.4 Regional Market Shares, 2023
    • 13.7.4 Product Benchmarking
    • 13.7.5 Strategic Outlook
  • 13.8 AstraZeneca
    • 13.8.1 Company Snapshot
    • 13.8.2 Company Overview
    • 13.8.3 Financial Analysis
      • 13.8.3.1 Net Revenue, 2019-2023
      • 13.8.3.2 R&D, 2019-2023
      • 13.8.3.3 Segment Market Shares, 2023
      • 13.8.3.4 Regional Market Shares, 2023
    • 13.8.4 Product Benchmarking
    • 13.8.5 Strategic Outlook
  • 13.9 Lilly
    • 13.9.1 Company Snapshot
    • 13.9.2 Company Overview
    • 13.9.3 Financial Analysis
      • 13.9.3.1 Net Revenue, 2019-2023
      • 13.9.3.2 R&D, 2019-2023
      • 13.9.3.3 Regional Market Shares, 2023
    • 13.9.4 Product Benchmarking
    • 13.9.5 Strategic Outlook
  • 13.10 Pfizer Inc.
    • 13.10.1 Company Snapshot
    • 13.10.2 Company Overview
    • 13.10.3 Financial Analysis
      • 13.10.3.1 Net Revenue, 2019-2023
      • 13.10.3.2 R&D, 2019-2023
      • 13.10.3.3 Segment Market Shares, 2023
      • 13.10.3.4 Regional Market Shares, 2023
    • 13.10.4 Product Benchmarking
    • 13.10.5 Strategic Outlook
  • 13.11 Johnson & Johnson Services, Inc.
    • 13.11.1 Company Snapshot
    • 13.11.2 Company Overview
    • 13.11.3 Financial Analysis
      • 13.11.3.1 Net Revenue, 2019-2023
      • 13.11.3.2 R&D, 2019-2023
      • 13.11.3.3 Segment Market Shares, 2023
      • 13.11.3.4 Regional Market Shares, 2023
    • 13.11.4 Product Benchmarking
    • 13.11.5 Strategic Outlook
  • 13.12 GSK plc
    • 13.12.1 Company Snapshot
    • 13.12.2 Company Overview
    • 13.12.3 Financial Analysis
      • 13.12.3.1 Net Revenue, 2019-2023
      • 13.12.3.2 R&D, 2019-2023
      • 13.12.3.3 Segment Market Shares, 2023
      • 13.12.3.4 Regional Market Shares, 2023
    • 13.12.4 Product Benchmarking
    • 13.12.5 Strategic Outlook
  • 13.13 Gilead Sciences, Inc.
    • 13.13.1 Company Snapshot
    • 13.13.2 Company Overview
    • 13.13.3 Financial Analysis
      • 13.13.3.1 Net Revenue, 2019-2023
      • 13.13.3.2 R&D, 2019-2023
      • 13.13.3.3 Segment Market Shares, 2023
      • 13.13.3.4 Regional Market Shares, 2023
    • 13.13.4 Product Benchmarking
    • 13.13.5 Strategic Outlook
  • 13.14 Amgen Inc.
    • 13.14.1 Company Snapshot
    • 13.14.2 Company Overview
    • 13.14.3 Financial Analysis
      • 13.14.3.1 Net Revenue, 2019-2023
      • 13.14.3.2 R&D, 2019-2023
      • 13.14.3.3 Regional Market Shares, 2023
    • 13.14.4 Product Benchmarking
    • 13.14.5 Strategic Outlook
  • 13.15 AbbVie Inc.
    • 13.15.1 Company Snapshot
    • 13.15.2 Company Overview
    • 13.15.3 Financial Analysis
      • 13.15.3.1 Net Revenue, 2019-2023
      • 13.15.3.2 R&D, 2019-2023
      • 13.15.3.3 Segment Market Shares, 2023
      • 13.15.3.4 Regional Market Shares, 2023
    • 13.15.4 Product Benchmarking
    • 13.15.5 Strategic Outlook
  • 13.16 Immunocore Ltd.
    • 13.16.1 Company Snapshot
    • 13.16.2 Company Overview
    • 13.16.3 Financial Analysis
      • 13.16.3.1 Net Revenue, 2019-2023
      • 13.16.3.2 R&D, 2019-2023
      • 13.16.3.3 Regional Market Shares, 2023
    • 13.16.4 Product Benchmarking
    • 13.16.5 Strategic Outlook
  • 13.17 Sanofi
    • 13.17.1 Company Snapshot
    • 13.17.2 Company Overview
    • 13.17.3 Financial Analysis
      • 13.17.3.1 Net Revenue, 2019-2023
      • 13.17.3.2 R&D, 2019-2023
      • 13.17.3.3 Segment Market Shares, 2023
      • 13.17.3.4 Regional Market Shares, 2023
    • 13.17.4 Product Benchmarking
    • 13.17.5 Strategic Outlook
  • 13.18 Takeda Pharmaceutical Company Limited.
    • 13.18.1 Company Snapshot
    • 13.18.2 Company Overview
    • 13.18.3 Financial Analysis
      • 13.18.3.1 Net Revenue, 2019-2023
      • 13.18.3.2 R&D, 2019-2023
      • 13.18.3.3 Segment Market Shares, 2023
      • 13.18.3.4 Regional Market Shares, 2023
    • 13.18.4 Product Benchmarking
    • 13.18.5 Strategic Outlook

14 Conclusion and Recommendations

  • 14.1 Concluding Remarks from Visiongain
  • 14.2 Recommendations for Market Players

List of Tables

  • Table 1 Cancer Immunotherapy Snapshot, 2024 & 2034 (US$ Billion, CAGR %)
  • Table 2 Cancer Immunotherapy Market Forecast by Technology 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 3 Types of Monoclonal Antibodies
  • Table 4 Types of Monoclonal Antibodies and Approval Status
  • Table 5 Monoclonal Antibodies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 6 Immunomodulators Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 7 Other Technology Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 8 Cancer Immunotherapy Market by Application, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 9 Types of Monoclonal Antibodies
  • Table 10 Lung Cancer Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 11 Breast Cancer Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 12 Colorectal Cancer Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 13 Melanoma Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 14 Prostate Cancer Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 15 Head & Neck Cancer Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 16 Ovarian Cancer Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 17 Pancreatic Cancer Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 18 Others Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 19 Cancer Immunotherapy Market by End-users, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 20 Hospitals Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 21 Cancer Research Centers Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 22 Clinics Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 23 Cancer Immunotherapy Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 24 North America Cancer Immunotherapy Market Forecast by Country, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 25 North America Cancer Immunotherapy Market Forecast by Technology, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 26 North America Cancer Immunotherapy Market Forecast by Application, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 27 North America Cancer Immunotherapy Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 28 U.S. Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 29 Canada Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 30 Europe Cancer Immunotherapy Market Forecast by Country, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 31 Europe Cancer Immunotherapy Market Forecast by Technology, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 32 Europe Cancer Immunotherapy Market Forecast by Application, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 33 Europe Cancer Immunotherapy Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 34 Germany Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 35 UK Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 36 France Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 37 Italy Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 38 Spain Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 39 Switzerland Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 40 Netherlands Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 41 Rest of Europe Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 42 Asia Pacific Cancer Immunotherapy Market Forecast by Country, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 43 Asia Pacific Cancer Immunotherapy Market Forecast by Technology, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 44 Asia Pacific Cancer Immunotherapy Market Forecast by Application, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 45 Asia Pacific Cancer Immunotherapy Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 46 Japan Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 47 China Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 48 India Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 49 Australia Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 50 South Korea Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 51 South East Asia Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 52 Rest of Asia Pacific Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 53 Latin America Cancer Immunotherapy Market Forecast by Country, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 54 Latin America Cancer Immunotherapy Market Forecast by Technology, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 55 Latin America Cancer Immunotherapy Market Forecast by Application, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 56 Latin America Cancer Immunotherapy Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 57 Brazil Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 58 Mexico Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 59 Argentina Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 60 Rest of Latin America Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 61 MEA Cancer Immunotherapy Market Forecast by Country, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 62 MEA Cancer Immunotherapy Market Forecast by Technology, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 63 MEA Cancer Immunotherapy Market Forecast by Application, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 64 MEA Cancer Immunotherapy Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 65 GCC Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 66 South Africa Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 67 Egypt Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 68 Rest of MEA Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 69 Strategic Outlook
  • Table 70 F. Hoffmann-La Roche Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 71 F. Hoffmann-La Roche Ltd. : Product Benchmarking
  • Table 72 F. Hoffmann-La Roche Ltd.: Strategic Outlook
  • Table 73 Merck & Co., Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 74 Merck & Co., Inc.: Product Benchmarking
  • Table 75 Merck & Co., Inc.: Strategic Outlook
  • Table 76 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 77 Novartis AG: Product Benchmarking
  • Table 78 Novartis AG: Strategic Outlook
  • Table 79 Bristol-Myers Squibb Company: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 80 Bristol-Myers Squibb Company: Product Benchmarking
  • Table 81 Bristol-Myers Squibb Company: Strategic Outlook
  • Table 82 Bayer AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 83 Bayer AG: Product Benchmarking
  • Table 84 Bayer AG: Strategic Outlook
  • Table 85 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 86 AstraZeneca: Product Benchmarking
  • Table 87 AstraZeneca: Strategic Outlook
  • Table 88 Lilly.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 89 Lilly.: Product Benchmarking
  • Table 90 Lilly: Strategic Outlook
  • Table 91 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 92 Pfizer Inc.: Product Benchmarking
  • Table 93 Pfizer Inc.: Strategic Outlook
  • Table 94 Johnson & Johnson Services, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 95 Johnson & Johnson Services, Inc.: Product Benchmarking
  • Table 96 Johnson & Johnson Services, Inc.: Strategic Outlook
  • Table 97 GSK plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 98 GSK plc: Product Benchmarking
  • Table 99 GSK plc: Strategic Outlook
  • Table 100 Gilead Sciences, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 101 Gilead Sciences, Inc.: Product Benchmarking
  • Table 102 Gilead Sciences, Inc.: Strategic Outlook
  • Table 103 Amgen Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 104 Amgen Inc.: Product Benchmarking
  • Table 105 Amgen Inc.: Strategic Outlook
  • Table 106 AbbVie Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 107 AbbVie Inc.: Product Benchmarking
  • Table 108 AbbVie Inc.: Strategic Outlook
  • Table 109 Immunocore Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 110 Immunocore Ltd.: Product Benchmarking
  • Table 111 Immunocore Ltd.: Strategic Outlook
  • Table 112 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 113 Sanofi: Product Benchmarking
  • Table 114 Sanofi: Strategic Outlook
  • Table 115 Takeda Pharmaceutical Company Limited.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 116 Takeda Pharmaceutical Company Limited.: Product Benchmarking
  • Table 117 Takeda Pharmaceutical Company Limited.: Strategic Outlook

List of Figures

  • Figure 1 Cancer Immunotherapy Market Segmentation
  • Figure 2 Cancer Immunotherapy Market Attractiveness Index by Region
  • Figure 3 Cancer Immunotherapy Market by Technology: Market Attractiveness Index
  • Figure 4 Cancer Immunotherapy Market by Application: Market Attractiveness Index
  • Figure 5 Cancer Immunotherapy Market by End-users: Market Attractiveness Index
  • Figure 6 Cancer Immunotherapy Market: Market Dynamics
  • Figure 7 Cancer Immunotherapy Market: Impact Analysis
  • Figure 8 Cancer Immunotherapy Industry: Supply Chain Analysis
  • Figure 9 Cancer Immunotherapy Market: Porter's Five Forces Analysis
  • Figure 10 Cancer Immunotherapy Market: PEST Analysis
  • Figure 11 Cancer Immunotherapy Market by Technology: Market Attractiveness Index
  • Figure 12 Cancer Immunotherapy Market Forecast by Technology, 2024-2034 (US$ Billion, AGR %)
  • Figure 13 Cancer Immunotherapy Market Share Forecast by Technology, 2024, 2029, 2034 (%)
  • Figure 14 Monoclonal Antibodies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 15 Monoclonal Antibodies Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 16 Immunomodulators Market Forecast by Region, 2024-2034 (US$ Billion)
  • Figure 17 Immunomodulators Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 18 Other Technology Market Forecast by Region, 2024-2034 (US$ Billion)
  • Figure 19 Other Technology Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 20 Cancer Immunotherapy Market by Application: Market Attractiveness Index
  • Figure 21 Cancer Immunotherapy Market by Application, 2024-2034 (US$ Billion)
  • Figure 22 Cancer Immunotherapy Market Share Forecast by Application, 2024, 2029, 2034 (%)
  • Figure 23 Lung Cancer Market Forecast by Region, 2024-2034 (US$ Billion)
  • Figure 24 Lung Cancer Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 25 Breast Cancer Market Forecast by Region, 2024-2034 (US$ Billion)
  • Figure 26 Breast Cancer Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 27 Colorectal Cancer Market Forecast by Region, 2024-2034 (US$ Billion)
  • Figure 28 Colorectal Cancer Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 29 Melanoma Market Forecast by Region, 2024-2034 (US$ Billion)
  • Figure 30 Melanoma Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 31 Prostate Cancer Market Forecast by Region, 2024-2034 (US$ Billion)
  • Figure 32 Prostate Cancer Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 33 Head & Neck Cancer Market Forecast by Region, 2024-2034 (US$ Billion)
  • Figure 34 Head & Neck Cancer Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 35 Ovarian Cancer Market Forecast by Region, 2024-2034 (US$ Billion)
  • Figure 36 Ovarian Cancer Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 37 Pancreatic Cancer Market Forecast by Region, 2024-2034 (US$ Billion)
  • Figure 38 Pancreatic Cancer Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 39 Others Market Forecast by Region, 2024-2034 (US$ Billion)
  • Figure 40 Others Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 41 Cancer Immunotherapy Market by End-users: Market Attractiveness Index
  • Figure 42 Cancer Immunotherapy Market by End-users, 2024-2034 (US$ Billion)
  • Figure 43 Cancer Immunotherapy Market Share by End-users, 2024, 2029, 2034 (%)
  • Figure 44 Hospitals Market Forecast by Region, 2024-2034 (US$ Billion)
  • Figure 45 Hospitals Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 46 Cancer Research Centers Market Forecast by Region, 2024-2034 (US$ Billion)
  • Figure 47 Cancer Research Centers Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 48 Clinics Market Forecast by Region, 2024-2034 (US$ Billion)
  • Figure 49 Clinics Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 50 Cancer Immunotherapy Market Forecast by Region 2024 and 2034 (Revenue, CAGR%)
  • Figure 51 Cancer Immunotherapy Market Share Forecast by Region 2024, 2029, 2034 (%)
  • Figure 52 Cancer Immunotherapy Market by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 53 North America Cancer Immunotherapy Market Attractiveness Index
  • Figure 54 North America Cancer Immunotherapy Market by Region, 2024, 2029 & 2034 (US$ Billion)
  • Figure 55 North America Cancer Immunotherapy Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
  • Figure 56 North America Cancer Immunotherapy Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 57 North America Cancer Immunotherapy Market Forecast by Technology, 2024-2034 (US$ Billion, AGR %)
  • Figure 58 North America Cancer Immunotherapy Market Share Forecast by Technology, 2024 & 2034 (%)
  • Figure 59 North America Cancer Immunotherapy Market Forecast by Application, 2024-2034 (US$ Billion, AGR %)
  • Figure 60 North America Cancer Immunotherapy Market Share Forecast by Application, 2024 & 2034 (%)
  • Figure 61 North America Cancer Immunotherapy Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %)
  • Figure 62 North America Cancer Immunotherapy Market Share Forecast by End-users, 2024 & 2034 (%)
  • Figure 63 U.S. Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 64 Canada Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 65 Europe Cancer Immunotherapy Market Attractiveness Index
  • Figure 66 Europe Cancer Immunotherapy Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • Figure 67 Europe Cancer Immunotherapy Market Forecast by Country, 2024-2034 (US$ Billion)
  • Figure 68 Europe Cancer Immunotherapy Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 69 Europe Cancer Immunotherapy Market Forecast by Technology, 2024-2034 (US$ Billion)
  • Figure 70 Europe Cancer Immunotherapy Market Share Forecast by Technology, 2024 & 2034 (%)
  • Figure 71 Europe Cancer Immunotherapy Market Forecast by Application, 2024-2034 (US$ Billion)
  • Figure 72 Europe Cancer Immunotherapy Market Share Forecast by Application, 2024 & 2034 (%)
  • Figure 73 Europe Cancer Immunotherapy Market Forecast by End-users, 2024-2034 (US$ Billion)
  • Figure 74 Europe Cancer Immunotherapy Market Share Forecast by End-users, 2024 & 2034(%)
  • Figure 75 Germany Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 76 UK Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 77 France Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 78 Italy Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 79 Spain Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 80 Switzerland Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 81 Netherlands Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 82 Rest of Europe Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 83 Asia Pacific Cancer Immunotherapy Market Attractiveness Index
  • Figure 84 Asia Pacific Cancer Immunotherapy Market by Region, 2024, 2029 & 2034 (US$ Billion)
  • Figure 85 Asia Pacific Cancer Immunotherapy Market Forecast by Country, 2024-2034 (US$ Billion)
  • Figure 86 Asia Pacific Cancer Immunotherapy Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 87 Asia Pacific Cancer Immunotherapy Market Forecast by Technology, 2024-2034 (US$ Billion)
  • Figure 88 Asia Pacific Cancer Immunotherapy Market Share Forecast by Technology, 2024 & 2034 (%)
  • Figure 89 Asia Pacific Cancer Immunotherapy Market Forecast by Application, 2024-2034 (US$ Billion)
  • Figure 90 Asia Pacific Cancer Immunotherapy Market Share Forecast by Application, 2024 & 2034 (%)
  • Figure 91 Asia Pacific Cancer Immunotherapy Market Forecast by End-users, 2024-2034 (US$ Billion)
  • Figure 92 Asia Pacific Cancer Immunotherapy Market Share Forecast by End-users, 2024 & 2034 (%)
  • Figure 93 Japan Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 94 China Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 95 India Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 96 Australia Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 97 South Korea Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 98 South East Asia Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 99 Rest of Asia Pacific Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 100 Latin America Cancer Immunotherapy Market Attractiveness Index
  • Figure 101 Latin America Cancer Immunotherapy Market by Region, 2024, 2029 & 2034 (US$ Billion)
  • Figure 102 Latin America Cancer Immunotherapy Market Forecast by Country, 2024-2034 (US$ Billion)
  • Figure 103 Latin America Cancer Immunotherapy Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 104 Latin America Cancer Immunotherapy Market Forecast by Technology, 2024-2034 (US$ Billion)
  • Figure 105 Latin America Cancer Immunotherapy Market Share Forecast by Technology, 2024 & 2034 (%)
  • Figure 106 Latin America Cancer Immunotherapy Market Forecast by Application, 2024-2034 (US$ Billion)
  • Figure 107 Latin America Cancer Immunotherapy Market Share Forecast by Application, 2024 & 2034 (%)
  • Figure 108 Latin America Cancer Immunotherapy Market Forecast by End-users, 2024-2034 (US$ Billion)
  • Figure 109 Latin America Cancer Immunotherapy Market Share Forecast by End-users, 2024 & 2034 (%)
  • Figure 110 Brazil Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 111 Mexico Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 112 Argentina Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 113 Rest of Latin America Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 114 MEA Cancer Immunotherapy Market Attractiveness Index
  • Figure 115 MEA Cancer Immunotherapy Market by Region, 2024, 2029 & 2034 (US$ Billion)
  • Figure 116 MEA Cancer Immunotherapy Market Forecast by Country, 2024-2034 (US$ Billion)
  • Figure 117 MEA Cancer Immunotherapy Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 118 MEA Cancer Immunotherapy Market Forecast by Technology, 2024-2034 (US$ Billion)
  • Figure 119 MEA Cancer Immunotherapy Market Share Forecast by Technology, 2024 & 2034 (%)
  • Figure 120 MEA Cancer Immunotherapy Market Forecast by Application, 2024-2034 (US$ Billion)
  • Figure 121 MEA Cancer Immunotherapy Market Share Forecast by Application, 2024 & 2034 (%)
  • Figure 122 MEA Cancer Immunotherapy Market Forecast by End-users, 2024-2034 (US$ Billion)
  • Figure 123 MEA Cancer Immunotherapy Market Share Forecast by End-users, 2024 & 2034 (%)
  • Figure 124 GCC Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 125 South Africa Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 126 Egypt Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 127 Rest of MEA Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 128 Cancer Immunotherapy Market: Company Share/Ranking, 2023
  • Figure 129 F. Hoffmann-La Roche Ltd.: Net Revenue, 2019-2023 (US$ Million, AGR %)
  • Figure 130 F. Hoffmann-La Roche Ltd.: R&D, 2019-2023 (US$ Million, AGR %)
  • Figure 131 F. Hoffmann-La Roche Ltd.: Segment Market Shares, 2023
  • Figure 132 F. Hoffmann-La Roche Ltd. Inc.: Regional Market Shares, 2023
  • Figure 133 Merck & Co., Inc.: Net Revenue, 2019-2023 (US$ Million, AGR %)
  • Figure 134 Merck & Co., Inc.: R&D, 2019-2023 (US$ Million, AGR %)
  • Figure 135 Merck & Co., Inc.: Segment Market Shares, 2023
  • Figure 136 Merck & Co., Inc.: Regional Market Shares, 2023
  • Figure 137 Novartis AG: Net Revenue, 2019-2023 (US$ Million, AGR %)
  • Figure 138 Novartis AG: R&D, 2019-2023 (US$ Million, AGR %)
  • Figure 139 Novartis AG: Segment Market Shares, 2023
  • Figure 140 Novartis AG: Regional Market Shares, 2023
  • Figure 141 Bristol-Myers Squibb Company: Net Revenue, 2019-2023 (US$ Million, AGR %)
  • Figure 142 Bristol-Myers Squibb Company : R&D, 2019-2023 (US$ Million, AGR %)
  • Figure 143 Bristol-Myers Squibb Company: Segment Market Shares, 2023
  • Figure 144 Bristol-Myers Squibb Company: Regional Market Shares, 2023
  • Figure 145 Bayer AG: Net Revenue, 2019-2023 (US$ Million, AGR (%)
  • Figure 146 Bayer AG: R&D, 2019-2023 (US$ Million, AGR %)
  • Figure 147 Bayer AG: Segment Market Shares, 2023
  • Figure 148 Bayer AG: Regional Market Shares, 2023
  • Figure 149 AstraZeneca: Net Revenue, 2019-2023 (US$ Million, AGR (%)
  • Figure 150 AstraZeneca: R&D, 2019-2023 (US$ Million, AGR %)
  • Figure 151 AstraZeneca: Segment Market Shares, 2023
  • Figure 152 AstraZeneca: Regional Market Shares, 2023
  • Figure 153 Lilly: Net Revenue, 2019-2023 (US$ Million, AGR (%)
  • Figure 154 Lilly: R&D, 2019-2023 (US$ Million, AGR %)
  • Figure 155 Lilly: Regional Market Shares, 2023
  • Figure 156 Pfizer Inc.: Net Revenue, 2019-2023 (US$ Million, AGR %)
  • Figure 157 Pfizer Inc.: R&D, 2019-2023 (US$ Million, AGR %)
  • Figure 158 Pfizer Inc.: Segment Market Shares, 2023
  • Figure 159 Pfizer Inc.: Regional Market Shares, 2023
  • Figure 160 Johnson & Johnson Services, Inc.: Net Revenue, 2019-2023 (US$ Million, AGR %)
  • Figure 161 Johnson & Johnson Services, Inc.: R&D, 2019-2023 (US$ Million, AGR %)
  • Figure 162 Johnson & Johnson Services, Inc.: Segment Market Shares, 2023
  • Figure 163 Johnson & Johnson Services, Inc.: Regional Market Shares, 2023
  • Figure 164 GSK plc: Net Revenue, 2019-2023 (US$ Million, AGR %)
  • Figure 165 GSK plc: R&D, 2019-2023 (US$ Million, AGR %)
  • Figure 166 GSK plc: Segment Market Shares, 2023
  • Figure 167 GSK plc: Regional Market Shares, 2023
  • Figure 168 Gilead Sciences, Inc.: Net Revenue, 2019-2023 (US$ Million, AGR %)
  • Figure 169 Gilead Sciences Inc.: R&D, 2019-2023 (US$ Million, AGR %)
  • Figure 170 Gilead Sciences, Inc.: Segment Market Shares, 2023
  • Figure 171 Gilead Sciences, Inc.: Regional Market Shares, 2023
  • Figure 172 Amgen Inc.: Net Revenue, 2019-2023 (US$ Million, AGR %)
  • Figure 173 Amgen Inc.: R&D, 2019-2023 (US$ Million, AGR %)
  • Figure 174 Amgen Inc.: Regional Market Shares, 2023
  • Figure 175 AbbVie Inc.: Net Revenue, 2019-2023 (US$ Million, AGR %)
  • Figure 176 AbbVie Inc.: R&D, 2019-2023 (US$ Million, AGR %)
  • Figure 177 AbbVie Inc.: Segment Market Shares, 2023
  • Figure 178 AbbVie Inc.: Regional Market Shares, 2023
  • Figure 179 Immunocore Ltd.: Net Revenue, 2019-2023 (US$ Million, AGR %)
  • Figure 180 Immunocore Ltd.: R&D, 2019-2023 (US$ Million, AGR %)
  • Figure 181 Immunocore Ltd.: Regional Market Shares, 2023
  • Figure 182 Sanofi: Net Revenue, 2019-2023 (US$ Million, AGR %)
  • Figure 183 Sanofi: R&D, 2019-2023 (US$ Million, AGR %)
  • Figure 184 Sanofi: Segment Market Shares, 2023
  • Figure 185 Sanofi: Regional Market Shares, 2023
  • Figure 186 Takeda Pharmaceutical Company Limited: Net Revenue, 2019-2023 (US$ Million, AGR %)
  • Figure 187 Takeda Pharmaceutical Company Limited: R&D, 2019-2023 (US$ Million, AGR %)
  • Figure 188 Takeda Pharmaceutical Company Limited: Segment Market Shares, 2023
  • Figure 189 Takeda Pharmaceutical Company Limited.: Regional Market Shares, 2023